<DrugInformationSummary id="CDR0000769403"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Lenvatinib mesylate works by blocking proteins that signal cancer cells to divide. It also blocks proteins that signal the growth of new blood vessels that tumors need to grow. Blocking these signals keeps cancer cells from growing. Lenvatinib mesylate is a type of targeted therapy drug called a kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily).</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/lenvatinibmesylate">Lenvatinib Mesylate</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000445461">lenvatinib mesylate</TerminologyLink><GlossaryLink ref="CDR0000769612">lenvatinib mesylate</GlossaryLink><USBrandNames><USBrandName>Lenvima</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>len-VA-tih-nib MEH-zih-layt</TermPronunciation><MediaLink ref="CDR0000771226" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000771225" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Lenvatinib Mesylate</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Lenvatinib mesylate
         is approved 
         to be used alone or with other drugs to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   
   
   <ListItem><Strong><GlossaryTermRef href="CDR0000444987" dictionary="Cancer.gov" audience="Patient">Endometrial carcinoma</GlossaryTermRef></Strong> that is <GlossaryTermRef href="CDR0000478743" dictionary="Cancer.gov" audience="Patient">advanced</GlossaryTermRef> and got worse after other <GlossaryTermRef href="CDR0000045922" dictionary="Cancer.gov" audience="Patient">systemic therapies</GlossaryTermRef>. It is used  with <GlossaryTermRef href="CDR0000764538" dictionary="Cancer.gov" audience="Patient">pembrolizumab</GlossaryTermRef> in patients whose cancer is not <GlossaryTermRef href="CDR0000285933" dictionary="Cancer.gov" audience="Patient">microsatellite instability</GlossaryTermRef>-high (MSI-H) or <GlossaryTermRef href="CDR0000789741" dictionary="Cancer.gov" audience="Patient">mismatch repair deficient</GlossaryTermRef> (dMMR) and cannot be treated with surgery or <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046363" dictionary="Cancer.gov" audience="Patient">Hepatocellular carcinoma</GlossaryTermRef></Strong>  (a type of <GlossaryTermRef href="CDR0000044242" dictionary="Cancer.gov" audience="Patient">liver cancer</GlossaryTermRef>). It is used as the first treatment in patients whose cancer cannot be removed by surgery.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000661352" dictionary="Cancer.gov" audience="Patient">Renal cell carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000444995" dictionary="Cancer.gov" audience="Patient">kidney cancer</GlossaryTermRef>) that is advanced. It is used:<ItemizedList Style="bullet" id="_5"><ListItem>With <GlossaryTermRef href="CDR0000386203" dictionary="Cancer.gov" audience="Patient">everolimus</GlossaryTermRef> in adults who have  received <GlossaryTermRef href="CDR0000046739" dictionary="Cancer.gov" audience="Patient">angiogenesis inhibitor</GlossaryTermRef> therapy.</ListItem><ListItem>With pembrolizumab as the first treatment in adults.</ListItem></ItemizedList> </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000445091" dictionary="Cancer.gov" audience="Patient">Thyroid cancer</GlossaryTermRef></Strong> in certain patients whose cancer got worse, came back, or has spread to other parts of the body and did not  respond to treatment with <GlossaryTermRef href="CDR0000045855" dictionary="Cancer.gov" audience="Patient">radioactive iodine</GlossaryTermRef>.</ListItem></ItemizedList>
  <Para id="_4">Lenvatinib mesylate
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Lenvatinib Mesylate</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/445461">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.16">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a615015.html">Lenvatinib Mesylate</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.17"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.18">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C48636">Find Clinical Trials for Lenvatinib Mesylate</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2015-02-26</DateFirstPublished><DateLastModified>2023-12-08</DateLastModified></DrugInformationSummary>
